Delivery Order SPE2DB24D2013-SPE2DB25FCJSK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,131.88 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jatenzo 158 mg capsules (120-count unit). This firm fixed-price delivery order, which is a child contract under a larger vehicle, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. The award utilized no set-aside designation and was competitively awarded through open...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Jatenzo 237 mg capsules (120 count), with a ceiling value of $2,479.28. This competitive delivery order, issued with firm fixed pricing, represents a non-set-aside award and is scheduled for ultimate completion by August 14, 2025. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Jatenzo 237 mg capsules (120-count) with a ceiling value of $1,303.86. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,283.72 to AmerisourceBergen Drug Corp for Jatenzo 237 mg capsules (120-count supply) on September 9, 2025, with completion scheduled for September 10, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,131.87. The contract is classified as a firm fixed price delivery order with an ultimate completion date of May 13, 2025, and represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 158 mg, valued at $1,142.26, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion prime vendor agreement designated SPE2DX and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $3,347.66 for Jatenzo 198 mg capsules (120-count units) with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a firm fixed price ceiling value of $1,483.15. This competitively awarded, non-set-aside delivery order is set for completion by September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,226.39. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside designation was used in this competitive award. The product...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJSKDelivery Order
The Defense Logistics Agency awarded a $8,442.15 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. The Jatenzo delivery represents a routine transaction within this expansive contract vehicle, which enables the company to supply specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 7/23/25 |